We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Ion Beam Applications SA (IBAB) NPV

Sell:€13.80 Buy:€14.38 Change: €0.26 (1.86%)
Market closed |  Prices as at close on 28 May 2024 | Switch to live prices |
Change: €0.26 (1.86%)
Market closed |  Prices as at close on 28 May 2024 | Switch to live prices |
Change: €0.26 (1.86%)
Market closed |  Prices as at close on 28 May 2024 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Ion Beam Applications SA (IBA) is a Belgium-based company that develops and markets technologies, pharmaceutical products and tailored solutions for the healthcare sector, with emphasis on cancer diagnosis and therapy. IBA is also active in the sterilization and ionization field. The Company operates through two business segments, namely the pharmaceuticals segment, which includes radiopharmaceuticals and the equipments segment, which encompasses proton therapy, particle accelerators and dosimetry. Through its various subsidiaries, Ion Beam Applications SA is active in a number of countries, including Belgium, Germany, France, Italy, Spain, the United Kingdom, Sweden, the United States, India and China. In November 2013, the Company announced the closing of the sale of 100% of its business unit Cisbio Bioassays.

Contact details

Chemin du Cyclotron 3
+32 (10) 475811

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
€423.95 million
Shares in issue:
29.16 million
Health Care Equipment
Euronext Brussels

Key personnel

  • Pierre Mottet
    Chairman of the Board, Representing Saint-Denis SA
  • Olivier Legrain
    Chief Executive Officer, Managing Director and Inside Director, Representative of Lamaris Group SRL
  • Soumya Chandramouli
    Chief Financial Officer, Member of the Management Board
  • Frederic Nolf
    Chief Human Resource and Sustainability Officer, Member of the Management Board
  • Yves Jongen
    Chief Research Officer, Managing Director, Internal Director, Representing Technofutur SA

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.